First Fiduciary Investment Counsel Inc. Takes Position in Eli Lilly and Company $LLY

First Fiduciary Investment Counsel Inc. purchased a new stake in Eli Lilly and Company (NYSE:LLY) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 500 shares of the company’s stock, valued at approximately $390,000.

A number of other large investors have also made changes to their positions in the company. Strengthening Families & Communities LLC increased its position in shares of Eli Lilly and Company by 723.1% in the 2nd quarter. Strengthening Families & Communities LLC now owns 107 shares of the company’s stock valued at $88,000 after buying an additional 94 shares in the last quarter. Strong Tower Advisory Services increased its position in shares of Eli Lilly and Company by 3.9% in the 2nd quarter. Strong Tower Advisory Services now owns 10,621 shares of the company’s stock valued at $8,279,000 after buying an additional 397 shares in the last quarter. PDS Planning Inc increased its position in shares of Eli Lilly and Company by 9.8% in the 2nd quarter. PDS Planning Inc now owns 7,382 shares of the company’s stock valued at $5,754,000 after buying an additional 660 shares in the last quarter. Gunderson Capital Management Inc. increased its position in shares of Eli Lilly and Company by 960.0% in the 2nd quarter. Gunderson Capital Management Inc. now owns 2,703 shares of the company’s stock valued at $2,107,000 after buying an additional 2,448 shares in the last quarter. Finally, Blue Trust Inc. increased its position in shares of Eli Lilly and Company by 76.6% in the 2nd quarter. Blue Trust Inc. now owns 90,111 shares of the company’s stock valued at $70,244,000 after buying an additional 39,094 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In related news, Director J Erik Fyrwald acquired 1,565 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Daniel Skovronsky acquired 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock worth $2,894,841 over the last three months. Company insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on LLY shares. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Cantor Fitzgerald set a $925.00 target price on Eli Lilly and Company and gave the stock an “overweight” rating in a report on Thursday. Guggenheim increased their target price on Eli Lilly and Company from $875.00 to $948.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $948.56.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $833.08 on Friday. The stock has a market capitalization of $788.47 billion, a price-to-earnings ratio of 54.45, a PEG ratio of 1.19 and a beta of 0.47. The business has a 50-day moving average of $742.42 and a 200-day moving average of $766.36. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter last year, the company earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.